FDA Approves Akeega (niraparib and abiraterone acetate) for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

HORSHAM, Pa., August 11, 2023– The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food& Drug Administration (FDA) has approved Akeega™ (niraparib and abiraterone acetate), the first-and-only...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news